Drug Interactions of Metformin Involving Drug Transporter Proteins

Naina Mohamed Pakkir Maideen ¹ * , Abdurazak Jumale ¹, Rajkapoor Balasubramaniam ²

Cited by CrossRef: 25

1- Saiti A, Giannopoulos-Dimitriou A, Kazakos I, Galatou E, Vizirianakis I. Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy. Future Pharmacology. 2023;3(1):329 [Crossref]

2- Maideen N. Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine. WJP. 2019;8(2):14 [Crossref]

3- Vallianou N, Stratigou T, Tsagarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones. 2019;18(2):141 [Crossref]

4- Song P, Hwang J, Park H, Kim K, Son H, Kim Y, Lee K. Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis. Pharmaceuticals. 2021;14(2):152 [Crossref]

5- Pakkir Maideen N. Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists. JAPLR. 2019;8(2):51 [Crossref]

6- Ailabouni A, Mettu V, Thakur A, Singh D, Prasad B. Effect of Cimetidine on Metformin Pharmacokinetics and Endogenous Metabolite Levels in Rats. Drug Metab Dispos. 2024;52(2):86 [Crossref]

7- Modesto A, Silveira E, dos Santos Rodrigues A, Lima D, Provin M, Amaral R. Prevalence of Drug Interaction in Severely Obese Individuals and Associated Factors: Baseline Results from a Clinical Trial. Sci Pharm. 2020;88(4):48 [Crossref]

8- Markowicz-Piasecka M, Sadowski K, Huttunen J, Sikora J, Huttunen K. Incorporation of Sulfonamide Moiety into Biguanide Scaffold Results in Apoptosis Induction and Cell Cycle Arrest in MCF-7 Breast Cancer Cells. IJMS. 2021;22(11):5642 [Crossref]

9- Ahmed EL-Arabey A, Abdalla M, Ali Eltayb W. Metformin: Ongoing Journey with Superdrug Revolution. Adv Pharm Bull. 2019;9(1):1 [Crossref]

10- Yendapally R, Sikazwe D, Kim S, Ramsinghani S, Fraser‐Spears R, Witte A, La‐Viola B. A review of phenformin, metformin, and imeglimin. Drug Development Research. 2020;81(4):390 [Crossref]

11- Kahraman C, Kaya Bilecenoglu D, Sabuncuoglu S, Cankaya I. Toxicology of pharmaceutical and nutritional longevity compounds. Expert Rev Mol Med. 2023;25 [Crossref]

12- Viera Y, Saavedra I, Rodríguez R, Martín N, Granados S, Cantón C. Metformin and diuretics. Nefrología (English Edition). 2019;39(5):557 [Crossref]

13- Garibsingh R, Schlessinger A. Advances and Challenges in Rational Drug Design for SLCs. Trends in Pharmacological Sciences. 2019;40(10):790 [Crossref]

14- Awang Jihadi M, Yuda A, Sukorini A, Hermansyah A, Shafqat N, Tan C, Ming L. Drug-related problems in hospitalized patients with type 2 diabetes mellitus: A systematic review. Exploratory Research in Clinical and Social Pharmacy. 2023;12:100348 [Crossref]

15- Sachar M, Kumar V, Gormsen L, Munk O, Unadkat J. Successful Prediction of Positron Emission Tomography–Imaged Metformin Hepatic Uptake Clearance in Humans Using the Quantitative Proteomics–Informed Relative Expression Factor Approach. Drug Metab Dispos. 2020;48(11):1210 [Crossref]

16- Rivero Viera Y, Auyanet Saavedra I, Guerra Rodríguez R, Esparza Martín N, Fernández Granados S, García Cantón C. Metformina y diuréticos. Nefrología. 2019;39(5):557 [Crossref]

17- Chen Y, Shan X, Luo C, He Z. Emerging nanoparticulate drug delivery systems of metformin. J Pharm Investig. 2020;50(3):219 [Crossref]

18- Popović K, Popović D, Miljković D, Popović J, Lalošević D, Čapo I. Co-treatment with nitroglycerin and metformin exhibits physicochemically and pathohistologically detectable anticancer effects on fibrosarcoma in hamsters. Biomedicine & Pharmacotherapy. 2020;130:110510 [Crossref]

19- Shibata M, Toyoshima J, Kaneko Y, Oda K, Nishimura T. A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers. Eur J Clin Pharmacol. 2020;76(8):1135 [Crossref]

20- Popović K, Popović D, Miljković D, Lalošević D, Čapo I, Popović J. Physicochemical and pathohistological changes in experimental fibrosarcoma tumors of hamsters treated with metformin and itraconazole. Oncol Lett. 2019; [Crossref]

21- Froldi G. View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences. Pharmaceuticals. 2024;17(4):478 [Crossref]

22- Modiwala M, Jadav T, Sahu A, Tekade R, Sengupta P. A Critical Review on Advancement in Analytical Strategies for the Quantification of Clinically Relevant Biological Transporters. Critical Reviews in Analytical Chemistry. 2022;52(7):1557 [Crossref]

23- Mohamed Pakkir Maideen N, Balasubramanian R, Muthusamy S, Nallasamy V. An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers. CCR. 2022;18(6) [Crossref]

24- Ramasubbu S, Mahato S, Agnihotri A, Pasricha R, Nath U, Das B. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. Cancer Treatment and Research Communications. 2021;26:100277 [Crossref]

25- Guarnaccia L, Marfia G, Masseroli M, Navone S, Balsamo M, Caroli M, Valtorta S, Moresco R, Campanella R, Garzia E, Riboni L, Locatelli M. Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma. Cancers. 2021;14(1):112 [Crossref]

26- Feng J, Wang X, Ye X, Ares I, Lopez-Torres B, Martínez M, Martínez-Larrañaga M, Wang X, Anadón A, Martínez M. Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications. Pharmacological Research. 2022;177:106114 [Crossref]

27- Maideen N. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023;59(2):115 [Crossref]